Symptoms of low mood and/or anxiety Mental and Behavioural Disorders
Conditions
Interventions
The study is a real-world quantitative evaluation to investigate the impact of Wysa therapeutics on clinical outcomes, as well as service benefits such as increased referrals and clinical/admin time s
Sponsors
Wysa Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Willing and able to provide informed consent 2. Aged 16 years or older 3. User is confident in their ability to speak and understand English at a proficient level 4. Own an electronic device capable of supporting Wysa 5. A valid email address, NHS number; phone number 6. Referred or self-referred to proceed through the standard IAPT care pathway
Exclusion criteria
Exclusion criteria: 1. Patients ineligible for the standard IAPT care pathway 2. Patients with previous and current known severe and enduring mental illnesses 3. Patients with current psychosis or a history of psychotic symptoms in the last 6 months 4. Patients with active suicidal ideation/ intent 5. Patients with significant cognitive disorders 6. Patients with a current diagnosis of a personality disorder 7. Patients with referrals for specialist presentations of pre-existing, diagnosed conditions requiring a specialised assessment beyond the standard clinical pathway 8. Not capable of providing self-consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Access to services will be measured by comparing referral numbers before and after the introduction of the Wysa Digital Referral Assistant. Time saved for clinicians will be measured using the time taken to reach a treatment outcome decision for patients who have completed the Wysa Digital Assistant compared with those who have not. 2. Clinical improvement measured using the Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) scores at referral, start of treatment and at discharge. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patient engagement and satisfaction with the app, measured through aggregated usage metrics collected by Wysa and app score ratings every 4 weeks 2. Functional impairment is measured using the Work and Social Adjustment Scale at the start and end of treatment | — |
Countries
England, United Kingdom
Outcome results
None listed